PROSTATE CANCER SCREENING USING THE PROSTATE-SPECIFIC ANTIGEN (PSA) TEST

descriptionPublicationkeyboard_double_arrow_right Article 30 Jun 2023Publisher:International Journal Of Advanced ResearchJournal:International Journal of Advanced Research, volume 11, pages 1,263-1,265 (eissn: 2320-5407,

Copyright policy )

Authors: Rahim Abbas;

doi: 10.21474/ijar01/17188 , 10.5281/zenodo.8199264 , 10.5281/zenodo.8199265

PROSTATE CANCER SCREENING USING THE PROSTATE-SPECIFIC ANTIGEN (PSA) TEST

- Summary
- Metrics

Abstract

We aimed to conduct a systematic review and meta-analysis on published literature extracted from PubMed/Medline, Google scholar, and Cochrane library. The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality reduction for the men screened in the intervention arm and a 23% negative impact on the life-years gained because of quality of life. However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, over diagnosis, and costs.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average